Merck KGaA

  • WKN: 659990
  • ISIN: DE0006599905
  • Land: Deutschland

Nachricht vom 04.05.2021 | 20:36

Merck KGaA raises forecast for full year 2021

Merck KGaA / Key word(s): Forecast/Change in Forecast
Merck KGaA raises forecast for full year 2021

04-May-2021 / 20:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre1 of EUR 1.51 bn and EPS pre1 of EUR 2.18, Merck KGaA (the "Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of approx. EUR 18.5 - 19.5 bn (previously "strong organic growth"). EBITDA pre1 is anticipated to grow to approx. EUR 5.4 - 5.8 bn for the group (previously "organic: high single-digit to low teens growth"). EPS pre1 is projected to amount to approx. EUR 7.50 - 8.20.

The Company will publish first-quarter 2021 figures as scheduled on 12 May 2021.

1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical shares outstanding (see Merck Annual Report 2020).

Andreas Cezanne, Head of Corporate Media Relations

04-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021